<DOC>
	<DOCNO>NCT00083707</DOCNO>
	<brief_summary>The purpose research study helpful thalidomide control disease study side effect take thalidomide .</brief_summary>
	<brief_title>Anti-Angiogenesis Therapy Using Thalidomide Patients With Waldenstrom 's Macroglobulinemia</brief_title>
	<detailed_description>Patients receive thalidomide oral form night bed . The dose thalidomide increase week week 7 long significant side effect . Routine physical examination blood test do monitor effect treatment toxicity encounter , , provide available treatment side effect accordingly . Blood test do monitor tumor response .</detailed_description>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must confirm diagnosis previously treat , active Waldenstrom 's Macroglobulinemia Patients must adequate hematologic function demonstrate total white blood count &gt; = 2000/mm3 , adequate renal function demonstrate serum creatinine &lt; = 3.0 mg/dl , adequate hepatic function demonstrate bilirubin &lt; = 1.5 mg/dl transaminase &lt; = 4 x ULN All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline No concurrent therapy WM permit thalidomide Pregnant nursing woman may participate . Before start treatment , woman childbearing potential negative pregnancy test perform within 24 hour prior begin therapy . Written report negative pregnancy test must obtain prescription thalidomide issue . Women/men reproductive potential may participate unless agree use effective contraceptive method . Pregnancy test require 1 ) woman postmenopausal least 2 year menses , 2 ) woman hysterectomy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Macroglobulinemia</keyword>
	<keyword>Waldenstrom</keyword>
	<keyword>Thalidomide</keyword>
</DOC>